APP 018
Alternative Names: APP-018; D-4FLatest Information Update: 09 Jul 2007
Price :
$50 *
At a glance
- Originator BruinPharma
- Class Cardiovascular therapies
- Mechanism of Action Apolipoprotein A-I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 22 Feb 2005 Phase-I clinical trials in Atherosclerosis in USA (PO)